Halep questions ‘disparate handling’ of doping cases after Swiatek’s ban

Simona Halep, a two-time Grand Slam winner who secured the French Open in 2018 and Wimbledon in 2019, has raised concerns regarding the “big difference” in the management of doping incidents within tennis, following the one-month suspension issued to world number two Iga Swiatek. The International Tennis Integrity Agency (ITIA) confirmed on Thursday that Ms. Swiatek had agreed to a one-month suspension after her test results indicated the presence of trimetazidine (TMZ), a prohibited substance. Ms. Halep, who experienced an absence from competition exceeding 18 months due to two distinct anti-doping infractions, has voiced criticism against the ITIA, citing their “completely different approaches.” On Friday, Ms. Halep shared her thoughts on Instagram, stating: “I stand and ask myself, why is there such a big difference in treatment and judgment?” She further added, “I can’t find and I don’t think there can be a logical answer. It can only be bad will from ITIA, the organization that has done absolutely everything to destroy me despite the evidence.” In October 2022, Ms. Halep received a provisional suspension after a test revealed the presence of roxadustat, a prohibited anti-anaemia medication known to stimulate red blood cell production in the body. Subsequently, the Romanian player received a four-year ban, which was later reduced to nine months in March following a successful appeal at the Court of Arbitration for Sport. Throughout this process, Ms. Halep consistently asserted her innocence, contending that she had ingested a contaminated supplement. The former world number one expressed her distress, stating: “I lost two years of my career, I lost many nights when I couldn’t sleep, thoughts, anxiety, questions without answers,” She then questioned, “How is it possible that in identical cases happening around the same time, ITIA to have completely different approaches to my detriment?” Ms. Swiatek’s positive test for TMZ, a heart medication, occurred in an out-of-competition sample collected in August 2024, during which period she held the world number one ranking. The ITIA acknowledged that the five-time major winner’s violation stemmed from the contamination of melatonin, a regulated non-prescription medication produced and distributed in Poland, which Ms. Swiatek consumed for jet lag and sleep difficulties. A spokesperson for the ITIA informed BBC Sport that “very important differences” existed between the circumstances of Ms. Halep’s case and those of Ms. Swiatek’s. The ITIA stated: “No two cases are the same, they often involve different circumstances, and direct comparisons are not always helpful,” adding, “The product contaminated in Ms Swiatek’s case was a regulated medication, not a supplement.” Ms. Swiatek’s suspension follows an incident in March where men’s world number one Jannik Sinner also tested positive for clostebol. While the ITIA determined that “no fault or negligence” was attributable to the 23-year-old Italian player, the World Anti-Doping Agency (Wada) has initiated an appeal to Cas. The ITIA commented: “We deal with each case based on the facts and evidence, not a player’s name, ranking or nationality. When a prohibited substance is found in a player’s system, we investigate it thoroughly.” They also advised, “We urge players to exercise extreme caution when taking supplements and we are always happy to answer any questions they have.”